January 31, 2015 : Episode 1

Video

Latest News & Insight: January 31, 2015

Related Videos
Jun Gong, MD
Alicia Morgans, MD, MPH, genitourinary medical oncologist, medical director, Survivorship Program, Dana-Farber Cancer Institute; associate professor, medicine, Harvard Medical School
Marc-Oliver Grimm, MD
Alicia Morgans, MD, MPH, genitourinary medical oncologist, medical director, Survivorship Program, Dana-Farber Cancer Institute; associate professor, medicine, Harvard Medical School
Stephen J. Freedland, MD, and Eleni Efstathiou, MD, PhD, experts on prostate cancer
Stephen J. Freedland, MD, and Eleni Efstathiou, MD, PhD, experts on prostate cancer
Jun Gong, MD, associate professor, medicine, medical oncologist, Gastrointestinal Disease Research Group, Pancreatic Cancer Research Group, Urologic Oncology Program, Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai
Marc-Oliver Grimm, MD
2 KOLs are featured in this panel.
2 KOLs are featured in this panel.
Related Content
Christian Behrenbruch PhD, MBA
July 24th 2024

FDA Accepts the New Drug Application for TLX007-CDx Kit in Prostate Cancer

Neeraj Agarwal, MD
July 17th 2023

FDA Approval Insights: Talazoparib Plus Enzalutamide in HRR Gene–Mutated mCRPC

Rahul Aggarwal, MD, of UCSF Helen Diller Family Comprehensive Cancer Center
July 11th 2024

Tarlatamab Monotherapy Is Safe, Active in DLL3+ Neuroendocrine Prostate Cancer

Andrew J. Armstrong, MD, MSc
June 15th 2023

FDA Approval Insights: Olaparib Plus Abiraterone in BRCA-Mutated mCRPC

S. Lindsey Davis, MD, oncologist, University of Colorado Cancer Center; associate professor, medicine-medical oncology, University of Colorado Anschutz Medical Campus
July 5th 2024

The Role of mTOR/Aurora A Kinase Combination Therapy Requires Further Elucidation in Solid Tumors

Steffen Heeger, MD, MSc
July 3rd 2024

FDA Grants Fast Track Designation to 225Ac-FL-020 for mCRPC